Project description:Biologic agents active in other autoimmune settings have had variable effectiveness in newly diagnosed type 1 diabetes (T1D) where treatment across therapeutic targets is accompanied by transient stabilization of C-peptide levels in some patients, followed by progression at the same rate as in control groups. Why disparate treatments lead to similar clinical courses is currently unknown. Here, we use integrated systems biology and flow cytometry approaches to elucidate immunologic mechanisms associated with C-peptide stabilization in T1D subjects treated with the anti-CD3 monoclonal antibody, teplizumab.

2016-12-06 | GSE84934 | GEO

Rituximab and cytokine release syndrome.

Project description: Not available

| S-EPMC3364040 | biostudies-literature

Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy.

Project description: Not available

| S-EPMC9518648 | biostudies-literature

A Computational Model of Cytokine Release Syndrome during CAR T-cell Therapy.

Project description: Not available

| S-EPMC9797206 | biostudies-literature

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Project description: Not available